ClinicalTrials.gg
CompletedNCT00683475Updated Oct 16, 2014Results posted

A Study of IMC-A12 or Ramucirumab Plus Mitoxantrone and Prednisone in Prostate Cancer

A Phase 2 interventional study of IMC-A12 and Mitoxantrone in Prostate Cancer, sponsored by Eli Lilly and Company. Completed at 36 sites in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-10-16.

Sponsored by Eli Lilly and Company · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
138
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Prostatic Neoplasms by Eli Lilly and Company — 2 open to participants now, 8 under way, 3 of them phase 3. Prostatic Neoplasms · Eli Lilly and Company.

Enrollment
12th of 19
138 · median 142
Started
2008
with 1 other
Phase 2
9 of 20
none open now
Registered
5th of 20
by date

Among the 20 studies in Prostatic Neoplasms by Eli Lilly and Company, this one is the 12th largest by enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2008, is one of 9 in phase 2, and was the 5th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

2 of the 20 studies in Prostatic Neoplasms by Eli Lilly and Company are open now, in 10 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Prostatic Neoplasms by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to determine whether IMC-A12 or IMC-1121B (ramucirumab) with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer (APIC).

Read the detailed description

Prostate cancer is the most frequently diagnosed cancer in men and the second leading cause of cancer-related death in men in the United States. Chemotherapy, either as a single agent or in combination, may lead to clinical response, pain control, and/or improved quality of life. Docetaxel is now the first-line standard therapy for AIPC. Mitoxantrone was approved in 1996 for use in combination with corticosteroids as initial chemotherapy for pain related to advanced Hormone Refractory Prostate Cancer (HRPC). Hormonal manipulations and docetaxel-based chemotherapy are often effective in metastatic prostate cancer; however, disease becomes refractory to these interventions in the majority of men. Although mitoxantrone continues to be a significant agent in the treatment of HRPC, there exists a need for more efficacious therapy in docetaxel-refractory- AIPC. Because of the potential contribution of Insulin Like Growth Factor Receptor (IGF-IR) and VEGFR-2 mediated pathways in prostate cancer pathogenesis, it is hypothesized that each of these biological agents in combination with mitoxantrone and prednisone will result in clinically meaningful activity in AIPC. Therefore, ImClone plans to conduct a randomized Phase 2 trial to assess the safety and efficacy of IMC-A12 or IMC-1121B (ramucirumab) in combination with mitoxantrone and prednisone in participants with AIPC.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria:

  • The participant has -confirmed adenocarcinoma of the prostate
  • The participant has radiographic evidence of prostate cancer (stage M1 or D2)
  • The participant has prostate cancer unresponsive or to hormone therapy (androgen-independent)
  • The participant has had disease progression (clinical or radiographic) while receiving docetaxel, or within 120 days of receiving docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive significant benefit from additional docetaxel-based therapy, or was intolerant to therapy with this agent
  • The participant must have evidence of progressive disease defined as at least one of the following;

    1. Progressive : using conventional solid tumor criteria
    2. Bone scan progression: at least two new lesions on bone scan
    3. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2
  • The participant has a PSA ≥ 2 ng/mL
  • The participant has prior surgical or medical castration with a serum testosterone of \<50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the participant must be willing to continue the use of LHRH agonists during protocol treatment
  • The participant has an performance status (ECOG PS) 0-2
  • The participant has adequate hematologic function ( [ANC]≥1500/uL, ≥9 g/dL, and ≥100,000/uL)
  • The participant has adequate hepatic function ( ≤ 1.5 times the (ULN), (AST) and Alanine Transaminase (ALT) ≤ 3 times the ULN, or ≤ 5 times the ULN if liver metastases are present)
  • The participant has adequate renal function (creatinine ≤ 1.5 x ULN or calculated > 40 mL/min)
  • The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \< 1000 mg of protein in 24 hours to allow participation in the study
  • The participant has adequate coagulation function (an [INR] ≤ 1.5 and a Partial Thromboplastin Time [PTT] ≤ 5 seconds above the ULN [unless on oral anticoagulant therapy]). Participants receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (and if on warfarin have a therapeutic INR between 2 and 3)
  • The participant has a fasting serum glucose level of \< 160 mg/dL, or below the ULN

Exclusion Criteria:

  • The participant has received more than one prior cytotoxic chemotherapy regimen for metastatic disease. (Participants who have had a treatment break followed by a second docetaxel-based regimen with subsequent disease progression are eligible.)
  • The participant has received prior therapy with mitoxantrone for advanced prostate cancer (prior therapy with mitoxantrone is permitted)
  • The participant has a history of symptomatic congestive heart failure or has a pre-study echocardiogram or multigated acquisition () scan with left ventricular ejection fraction (LVEF) that is ≥ 10% below the LLN
  • The participant has received radiotherapy ≤ 21 days prior to first dose of IMC-A12 or Ramucirumab
  • The participant is receiving (dexamethasone, prednisone, or others) at a dose > 5 mg prednisone orally (PO) two times per day (BID) or equivalent. Participants receiving corticosteroids at higher doses may be eligible if their corticosteroid therapy is tapered to study levels (prednisone 5 mg PO BID) prior to first dose of study medication, without concomitant clinical deterioration
  • The participant has known or suspected brain or
  • The participant has uncontrolled or poorly controlled hypertension
  • The participant has poorly controlled diabetes mellitus. Inclusion Criteria:
  • The participant has histologically-confirmed adenocarcinoma of the prostate
  • The participant has radiographic evidence of metastatic prostate cancer (stage M1 or D2)
  • The participant has prostate cancer unresponsive or refractory to hormone therapy (androgen-independent)
  • The participant has had disease progression (clinical or radiographic) while receiving docetaxel, or within 120 days of receiving docetaxel-based chemotherapy and in the opinion of the investigator is unlikely to derive significant benefit from additional docetaxel-based therapy, or was intolerant to therapy with this agent
  • The participant must have evidence of progressive disease defined as at least one of the following;

    1. Progressive measurable disease: using conventional solid tumor criteria
    2. Bone scan progression: at least two new lesions on bone scan
    3. Increasing PSA: at least two consecutive rising PSA values over a reference value (PSA #1) taken at least 1 week apart. A third PSA (PSA #3) is required to be greater than PSA #2; if not, a fourth PSA (PSA #4) is required to be greater than PSA #2
  • The participant has a PSA ≥ 2 ng/mL
  • The participant has prior surgical or medical castration with a serum testosterone of \<50 ng/mL. If the method of castration is luteinizing hormone releasing level hormone (LHRH) agonists, the participant must be willing to continue the use of LHRH agonists during protocol treatment
  • The participant has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0-2
  • The participant has adequate hematologic function (absolute neutrophil count [ANC]≥1500/uL, hemoglobin ≥9 g/dL, and platelets ≥100,000/uL)
  • The participant has adequate hepatic function (bilirubin ≤ 1.5 times the upper limit of normal (ULN), aspartate transaminase [AST] and alanine transaminase [ALT]≤ 3 times the ULN, or ≤ 5 times the ULN if liver metastases are present)
  • The participant has adequate renal function (creatinine ≤ 1.5 x ULN or calculated creatinine clearance > 40 mL/min)
  • The participant's urinary protein is ≤ 1+ on dipstick or routine urinalysis (UA). If urine dipstick or routine analysis indicates ≥ 2+ proteinuria, then a 24-hour urine must be collected and must demonstrate \< 1000 mg of protein in 24 hours to allow participation in the study
  • The participant has adequate coagulation function (an international normalized ratio [INR] ≤ 1.5 and a partial thromboplastin time [PTT] ≤ 5 seconds above the ULN [unless on oral anticoagulant therapy]). Participants receiving full-dose anticoagulation therapy are eligible provided they meet all other criteria, are on a stable dose of oral anticoagulant or low molecular weight heparin (and if on warfarin have a therapeutic INR between 2 and 3)
  • The participant has a fasting serum glucose level of \< 160 mg/dL, or below the ULN

Exclusion Criteria:

  • The participant has received more than one prior cytotoxic chemotherapy regimen for metastatic disease. (Participants who have had a treatment break followed by a second docetaxel-based regimen with subsequent disease progression are eligible.)
  • The participant has received prior therapy with mitoxantrone for advanced prostate cancer (prior adjuvant therapy with mitoxantrone is permitted)
  • The participant has a history of symptomatic congestive heart failure or has a pre-study echocardiogram or multigated acquisition (MUGA) scan with left ventricular ejection fraction (LVEF) that is ≥ 10% below the LLN
  • The participant has received radiotherapy ≤ 21 days prior to first dose of IMC-A12 or Ramucirumab
  • The participant is receiving corticosteroids (dexamethasone, prednisone, or others) at a dose > 5 mg prednisone orally (PO) two times per day (BID) or equivalent. Participants receiving corticosteroids at higher doses may be eligible if their corticosteroid therapy is tapered to study levels (prednisone 5 mg PO BID) prior to first dose of study medication, without concomitant clinical deterioration
  • The participant has known or suspected brain or leptomeningeal metastases
  • The participant has uncontrolled or poorly controlled hypertension
  • The participant has poorly controlled diabetes mellitus. Participants with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting \< 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition
  • The participant has a known infection or acquired immunodeficiency syndrome-related illness with a history of diabetes are allowed to participate, provided that their blood glucose is within normal range (fasting \< 120 mg/dL or below ULN) and that they are on a stable dietary or therapeutic regimen for this condition
  • The participant has a known human immunodeficiency virus infection or acquired immunodeficiency syndrome-related illness
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
138 participants (actual)

Study arms

  • Experimental
    IMC-1121B (ramucirumab) + Mitoxantrone + Prednisone

    Drug: Mitoxantrone · Drug: Prednisone · Biological: IMC-1121B (ramucirumab)

  • Experimental
    IMC-A12 + Mitoxantrone + Prednisone

    Biological: IMC-A12 · Drug: Mitoxantrone · Drug: Prednisone

Interventions

  • BiologicalIMC-A12

    IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.

    Also known as: cixutumumab, LY3012217

  • Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m\^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m\^2) or until there is evidence of disease progression, death, or intolerable toxicity.

  • Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.

  • IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.

    Also known as: ramucirumab, IMC-1121B, LY3009806

06

What researchers measure

Primary outcomes

  1. Composite Progression-free Survival (cPFS)

    Defined as the median time from randomization to the earliest of: 1. Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST); 2. Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of \>=2 new lesions; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression) 4. Symptomatic progression (for participants without measurable disease); 5. Other clinical events attributable to prostate cancer that require major interventions; or 6. Death from any cause Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

    Time frame: Randomization to composite progressive disease, up to 23.4 months

Secondary outcomes

  1. Summary Listing of Participants Reporting Treatment-Emergent Adverse Events

    Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.

    Time frame: Randomization to 36.3 months

  2. Time to Radiographic Evidence of Disease Progression

    Time between date of randomization and earliest date of radiographic progression defined as either: 1. Tumor progression by RECIST; 2. Evidence of progression by bone scan; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression). Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy.

    Time frame: Randomization to date of radiographic progression, up to 36.3 months

  3. Prostate Specific Antigen (PSA) Response Rate

    PSA response rate is defined as the percentage of participants with a decrease in PSA \>= 50 percent from baseline.

    Time frame: Baseline up to data cut-off date (up to 36.3 months)

  4. Composite Progression-free Survival (cPFS) at 6-months

    Data presented are the percentage of participants without disease progression at 6 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

    Time frame: 6 months

  5. Composite Progression-free Survival (cPFS) at 9-months

    Data presented are the percentage of participants without disease progression at 9 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

    Time frame: 9 months

  6. Composite Progression-free Survival (cPFS) at 12-months

    Data presented are the percentage of participants without disease progression at 12 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

    Time frame: 12 months

  7. Overall Survival (OS)

    Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive.

    Time frame: First dose to death due to any cause up to 36.3 months

  8. Objective Response Rate (ORR)

    Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.

    Time frame: Baseline to date of progressive disease or death up to 36.3 months

  9. Maximum Concentration (Cmax) at Study Day 1

    Maximum Concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 1

  10. Maximum Concentration (Cmax) at Study Day 15

    Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 15

  11. Maximum Concentration (Cmax) at Study Day 16

    Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 16

  12. Maximum Concentration (Cmax) at Study Day 30

    Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 30

  13. Minimum Concentration (Cmin) at Study Day 1

    Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 1

  14. Minimum Concentration (Cmin) at Study Day 15

    Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 15

  15. Minimum Concentration (Cmin) at Study Day 16

    Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 16

  16. Minimum Concentration (Cmin) at Study Day 30

    Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

    Time frame: Day 30

07

Results

Posted Jun 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Started6969
Received any quantity of study drug6666
Completed6566
Not completed43
Withdrew: Withdrawal by subject10
Withdrew: Never treated: adverse event23
Withdrew: Never treated: progressive disease10

Outcome measures

PrimaryComposite Progression-free Survival (cPFS)

Defined as the median time from randomization to the earliest of: 1. Tumor progression by Response Evaluation Criteria in Solid Tumors (RECIST); 2. Evidence of progression by bone scan, performed after completion of the first 3 cycles, demonstrating the appearance of \>=2 new lesions; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression) 4. Symptomatic progression (for participants without measurable disease); 5. Other clinical events attributable to prostate cancer that require major interventions; or 6. Death from any cause Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

Time frame:
Randomization to composite progressive disease, up to 23.4 months
Reported as:
Median · months
Composite Progression-free Survival (cPFS)
monthsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Composite Progression-free Survival (cPFS)4.1 (2.2 to 5.6)6.7 (4.5 to 8.3)
SecondarySummary Listing of Participants Reporting Treatment-Emergent Adverse Events

Data presented are the number of participants who experienced A12 or 1121B (ramucirumab) related treatment-emergent adverse events (TEAE), treatment related serious adverse events (SAE), or any Grade 3 or higher TEAE; any TEAE leading to discontinuation of A12 or 1121B (ramucirumab) treatment, and any TEAE leading to dose modification of A12 or 1121B (ramucirumab). A summary of SAEs and other nonserious AEs, regardless of causality, is located in the Reported Adverse Event section.

Time frame:
Randomization to 36.3 months
Reported as:
Number · participants
Summary Listing of Participants Reporting Treatment-Emergent Adverse Events
participantsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
A12/1121B Related TEAE6463
A12/1121B Related Serious TEAE2216
A12/1121B Related Grade >= 3 TEAE3531
TEAE Leading to Dose Modification of A12/1121B3535
TEAE Leading to Discontinuation of A12/1121B1825
SecondaryTime to Radiographic Evidence of Disease Progression

Time between date of randomization and earliest date of radiographic progression defined as either: 1. Tumor progression by RECIST; 2. Evidence of progression by bone scan; 3. New skeletal events (New pathologic bone fracture in the region of metastatic disease; New bone lesion requiring radiation or surgery; Spinal cord or nerve root compression). Participants who were ongoing with no radiographic evidence of disease progression, who discontinued treatment for reasons other than progression,or died before progression were censored at date of last tumor or bone radiographic assessment. Participants who started a new anticancer treatment before progression were censored at date of last tumor or bone radiographic assessment before start of new anti-cancer therapy.

Time frame:
Randomization to date of radiographic progression, up to 36.3 months
Reported as:
Median · months
Time to Radiographic Evidence of Disease Progression
monthsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Time to Radiographic Evidence of Disease Progression7.5 (4.8 to 10.1)10.2 (7.5 to 12.6)
SecondaryProstate Specific Antigen (PSA) Response Rate

PSA response rate is defined as the percentage of participants with a decrease in PSA \>= 50 percent from baseline.

Time frame:
Baseline up to data cut-off date (up to 36.3 months)
Reported as:
Number · percentage of participants
Prostate Specific Antigen (PSA) Response Rate
percentage of participantsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Prostate Specific Antigen (PSA) Response Rate18.5 (9.3 to 31.4)21.4 (11.6 to 34.4)
SecondaryComposite Progression-free Survival (cPFS) at 6-months

Data presented are the percentage of participants without disease progression at 6 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

Time frame:
6 months
Reported as:
Number · percentage of participants
Composite Progression-free Survival (cPFS) at 6-months
percentage of participantsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Composite Progression-free Survival (cPFS) at 6-months37.2 (25.0 to 49.4)59.2 (45.8 to 70.4)
SecondaryComposite Progression-free Survival (cPFS) at 9-months

Data presented are the percentage of participants without disease progression at 9 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

Time frame:
9 months
Reported as:
Number · percentage of participants
Composite Progression-free Survival (cPFS) at 9-months
percentage of participantsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Composite Progression-free Survival (cPFS) at 9-months20.7 (11.2 to 32.1)35.9 (23.4 to 48.5)
SecondaryComposite Progression-free Survival (cPFS) at 12-months

Data presented are the percentage of participants without disease progression at 12 months. Participants who were ongoing with no progression or who discontinued treatment for reasons other than progression were censored at date of last assessment. Participants who started new anticancer treatment before progression were censored at date of last assessment before start of new anti-cancer therapy.

Time frame:
12 months
Reported as:
Number · percentage of participants
Composite Progression-free Survival (cPFS) at 12-months
percentage of participantsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Composite Progression-free Survival (cPFS) at 12-months12.4 (5.2 to 22.9)20.0 (10.1 to 32.3)
SecondaryOverall Survival (OS)

Overall survival is defined as the time from randomization to the date of death due to any cause. Participants who were alive at the time of study completion were censored at the time the participant was last known to be alive.

Time frame:
First dose to death due to any cause up to 36.3 months
Reported as:
Median · months
Overall Survival (OS)
monthsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Overall Survival (OS)10.8 (6.5 to 13.0)13.0 (9.5 to 16.0)
SecondaryObjective Response Rate (ORR)

Objective response is Complete Response (CR) + Partial Response (PR), as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST) guidelines. CR is a disappearance of all target and non-target lesions; PR is at least a 30% decrease in the sum of the longest diameter of target lesions without new lesions and progression of non-target lesions. Objective response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with measurable disease, multiplied by 100.

Time frame:
Baseline to date of progressive disease or death up to 36.3 months
Reported as:
Number · percentage of participants
Objective Response Rate (ORR)
percentage of participantsIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
Objective Response Rate (ORR)15.2 (6.3 to 28.9)31.6 (17.5 to 48.7)
SecondaryMaximum Concentration (Cmax) at Study Day 1

Maximum Concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 1

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) at Study Day 15

Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 15

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) at Study Day 16

Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 16

No measurements were reported for this outcome.

SecondaryMaximum Concentration (Cmax) at Study Day 30

Maximum concentration (Cmax) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 30

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Study Day 1

Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 1

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Study Day 15

Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 15

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Study Day 16

Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 16

No measurements were reported for this outcome.

SecondaryMinimum Concentration (Cmin) at Study Day 30

Minimum concentration (Cmin) of Ramucirumab. All samples were assayed 36 months post sample collection, which exceeds the established long-term serum stability period for ramucirumab. Therefore, concentration data were invalid and pharmacokinetic (PK) analyses could not be conducted.

Time frame:
Day 30

No measurements were reported for this outcome.

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
IMC-A12 + Mitoxantrone + Prednisone—40/66 (60.6%)65/66 (98.5%)
IMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone—36/66 (54.5%)66/66 (100%)
Most frequent serious events
Showing 10 of 92
Most frequent serious events
EventIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
DISEASE PROGRESSIONGeneral disorders8/662/66
MEDICATION ERRORInjury, poisoning and procedural complications0/664/66
DEHYDRATIONMetabolism and nutrition disorders4/661/66
BACK PAINMusculoskeletal and connective tissue disorders4/661/66
DIARRHOEAGastrointestinal disorders3/661/66
EXPIRED DRUG ADMINISTEREDInjury, poisoning and procedural complications0/663/66
SYNCOPENervous system disorders3/660/66
FEBRILE NEUTROPENIABlood and lymphatic system disorders2/662/66
LEUKOPENIABlood and lymphatic system disorders1/662/66
NEUTROPENIABlood and lymphatic system disorders2/661/66
Most frequent other events
Showing 10 of 75
Most frequent other events
EventIMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + Prednisone
FATIGUEGeneral disorders48/6647/66
WEIGHT DECREASEDInvestigations43/6640/66
ANOREXIAMetabolism and nutrition disorders35/6631/66
NAUSEAGastrointestinal disorders34/6631/66
HYPERGLYCAEMIAMetabolism and nutrition disorders31/668/66
DIARRHOEAGastrointestinal disorders29/6629/66
NEUTROPENIABlood and lymphatic system disorders28/6624/66
CONSTIPATIONGastrointestinal disorders27/6624/66
ANAEMIABlood and lymphatic system disorders23/6623/66
THROMBOCYTOPENIABlood and lymphatic system disorders12/6623/66

Baseline characteristics

Modified intent to treat population (mITT): All participants who received any quantity of study drug.

Age, Categorical
Age, Categorical(Participants)IMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + PrednisoneTotal
<=18 years000
Between 18 and 65 years302151
>=65 years364581
Sex: Female, Male
Sex: Female, Male(Participants)IMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + PrednisoneTotal
Female000
Male6666132
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + PrednisoneTotal
Hispanic or Latino134
Not Hispanic or Latino6563128
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)IMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + PrednisoneTotal
White6158119
Black Or African American4610
Other123
Region of Enrollment
Region of Enrollment(participants)IMC-A12 + Mitoxantrone + PrednisoneIMC-1121B (Ramucirumab) + Mitoxantrone + PrednisoneTotal
United States6666132
08

Study locations

36 sites
  • ImClone Investigational Site
    La Jolla, California 92093, United States
  • ImClone Investigational Site
    New Haven, Connecticut 06520, United States
  • ImClone Investigational Site
    Boca Raton, Florida 33486, United States
  • ImClone Investigational Site
    Port St. Lucie, Florida 34952, United States
  • ImClone Investigational Site
    Atlanta, Georgia 30318, United States
  • ImClone Investigational Site
    Chicago, Illinois 60611, United States
  • ImClone Investigational Site
    Chlcago, Illinois 60637, United States
  • ImClone Investigational Site
    Evanston, Illinois 60201, United States
  • ImClone Investigational Site
    Maryville, Illinois 62062, United States
  • ImClone Investigational Site
    Cedar Rapids, Iowa 52402, United States
  • ImClone Investigational Site
    Metairie, Louisiana 70006, United States
  • ImClone Investigational Site
    Ann Arbor, Michigan 48109, United States
  • ImClone Investigational Site
    Rochester, Minnesota 55905, United States
  • ImClone Investigational Site
    St Louis, Missouri 63110, United States
  • ImClone Investigational Site
    Billings, Montana 59101, United States
  • ImClone Investigational Site
    Roseland, New Jersey 07068, United States
  • ImClone Investigational Site
    Buffalo, New York 14263, United States
  • ImClone Investigational Site
    East Setauket, New York 11733, United States
  • ImClone Investigational Site
    New York, New York 10016, United States
  • ImClone Investigational Site
    New York, New York 10019, United States
  • ImClone Investigational Site
    New York, New York 10021, United States
  • ImClone Investigational Site
    New York, New York 10032, United States
  • ImClone Investigational Site
    Durham, North Carolina 27710, United States
  • ImClone Investigational Site
    Cleveland, Ohio 44195, United States
  • ImClone Investigational Site
    Philadelphia, Pennsylvania 19111, United States
  • ImClone Investigational Site
    Pittsburgh, Pennsylvania 15232, United States
  • ImClone Investigational Site
    Greenville, South Carolina 29605, United States
  • ImClone Investigational Site
    Knoxville, Tennessee 37920, United States
  • ImClone Investigational Site
    Nashville, Tennessee 37203, United States
  • ImClone Investigational Site
    Abilene, Texas 79606, United States
  • ImClone Investigational Site
    Dallas, Texas 75246, United States
  • ImClone Investigational Site
    Houston, Texas 77030-4009, United States
  • ImClone Investigational Site
    Houston, Texas 77030, United States
  • ImClone Investigational Site
    Seattle, Washington 98104, United States
  • ImClone Investigational Site
    Seattle, Washington 98109, United States
  • ImClone Investigational Site
    Madison, Wisconsin 53792, United States
09

References and documents

Publications

  • Hussain M, Rathkopf D, Liu G, Armstrong A, Kelly WK, Ferrari A, Hainsworth J, Joshi A, Hozak RR, Yang L, Schwartz JD, Higano CS. A randomised non-comparative phase II trial of cixutumumab (IMC-A12) or ramucirumab (IMC-1121B) plus mitoxantrone and prednisone in men with metastatic docetaxel-pretreated castration-resistant prostate cancer. Eur J Cancer. 2015 Sep;51(13):1714-24. doi: 10.1016/j.ejca.2015.05.019. Epub 2015 Jun 13. PubMed 26082390 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2008, a primary completion of Sep 2011 and a completion of Sep 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2014, 2 years 9 months after primary completion. A results delay was requested in Aug 2010.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2008
First posted
May 23, 2008
Start
Aug 2008
Primary completionActual
Sep 2011
CompletionActual
Sep 2011
Results delay requested
Aug 25, 2010
Results first posted
Jun 18, 2014
Last update
Oct 16, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00683475
Responsible party
Sponsor
First posted
May 23, 2008
Start date
Aug 2008
Primary completion
Sep 2011
Completion
Sep 2011
Results posted
Jun 18, 2014
Last update
Oct 16, 2014

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cixutumumab · Ramucirumab

Start the discussion